281 related articles for article (PubMed ID: 20701410)
1. Adverse drug reaction reporting in the UK: a retrospective observational comparison of yellow card reports submitted by patients and healthcare professionals.
McLernon DJ; Bond CM; Hannaford PC; Watson MC; Lee AJ; Hazell L; Avery A;
Drug Saf; 2010 Sep; 33(9):775-88. PubMed ID: 20701410
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
3. How patient reporters identify adverse drug reactions: a qualitative study of reporting via the UK Yellow Card Scheme.
Krska J; Anderson C; Murphy E; Avery AJ
Drug Saf; 2011 May; 34(5):429-36. PubMed ID: 21513365
[TBL] [Abstract][Full Text] [Related]
4. How do patients contribute to signal detection? : A retrospective analysis of spontaneous reporting of adverse drug reactions in the UK's Yellow Card Scheme.
Hazell L; Cornelius V; Hannaford P; Shakir S; Avery AJ;
Drug Saf; 2013 Mar; 36(3):199-206. PubMed ID: 23444232
[TBL] [Abstract][Full Text] [Related]
5. First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals.
Durrieu G; Palmaro A; Pourcel L; Caillet C; Faucher A; Jacquet A; Ouaret S; Perault-Pochat MC; Kreft-Jais C; Castot A; Lapeyre-Mestre M; Montastruc JL;
Drug Saf; 2012 Oct; 35(10):845-54. PubMed ID: 22967189
[TBL] [Abstract][Full Text] [Related]
6. Patient views and experiences of making adverse drug reaction reports to the Yellow Card Scheme in the UK.
McLernon DJ; Bond CM; Lee AJ; Watson MC; Hannaford PC; Fortnum H; Krska J; Anderson C; Murphy E; Avery A;
Pharmacoepidemiol Drug Saf; 2011 May; 20(5):523-31. PubMed ID: 21328634
[TBL] [Abstract][Full Text] [Related]
7. Nonmedical prescriber experiences of training and competence to report adverse drug reactions in the UK.
Thompson A; Randall C; Howard J; Barker C; Bowden D; Mooney P; Munyika A; Smith S; Pirmohamed M
J Clin Pharm Ther; 2019 Feb; 44(1):78-83. PubMed ID: 30206951
[TBL] [Abstract][Full Text] [Related]
8. Reported paediatric adverse drug reactions in the UK 2000-2009.
Hawcutt DB; Mainie P; Riordan A; Smyth RL; Pirmohamed M
Br J Clin Pharmacol; 2012 Mar; 73(3):437-46. PubMed ID: 21988288
[TBL] [Abstract][Full Text] [Related]
9. Identifying and managing adverse drug reactions: Qualitative analysis of patient reports to the UK yellow card scheme.
O' Donovan B; Rodgers RM; Cox AR; Krska J
Br J Clin Pharmacol; 2022 Jul; 88(7):3434-3446. PubMed ID: 35128732
[TBL] [Abstract][Full Text] [Related]
10. The involvement of nurses in reporting suspected adverse drug reactions: experience with the meningococcal vaccination scheme.
Ranganathan SS; Houghton JE; Davies DP; Routledge PA
Br J Clin Pharmacol; 2003 Dec; 56(6):658-63. PubMed ID: 14616426
[TBL] [Abstract][Full Text] [Related]
11. Pharmacovigilance Reports Received from Children and Young People, and Development of Information to Aid Future Reporting from this Age Group.
Bhoombla N; Preston J; Ainsworth J; Bird H; Jadeja M; King C; Hawcutt DB
Paediatr Drugs; 2020 Jun; 22(3):335-341. PubMed ID: 32253722
[TBL] [Abstract][Full Text] [Related]
12. Adverse drug reaction reporting by patients in the Netherlands: three years of experience.
de Langen J; van Hunsel F; Passier A; de Jong-van den Berg L; van Grootheest K
Drug Saf; 2008; 31(6):515-24. PubMed ID: 18484785
[TBL] [Abstract][Full Text] [Related]
13. A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016.
Ogar CK; Abiola A; Yuah D; Ibrahim A; Oreagba IA; Amadi EC; Adeyeye MC; Oshikoya KA
Pharmaceut Med; 2019 Apr; 33(2):145-157. PubMed ID: 31933250
[TBL] [Abstract][Full Text] [Related]
14. Public awareness in Wales of the UK Yellow Card scheme for reporting suspected adverse drug reactions.
Bracchi RC; Tseliou F; Copeland L; Routledge PA; Thomas A; Woods F; Adams A; Walker J; Jadeja M; Atkinson MD; Ashfield-Watt P
Br J Clin Pharmacol; 2021 Aug; 87(8):3344-3348. PubMed ID: 33386761
[TBL] [Abstract][Full Text] [Related]
15. Interpreting adverse drug reaction (ADR) reports as hospital patient safety incidents.
Davies EC; Green CF; Mottram DR; Pirmohamed M
Br J Clin Pharmacol; 2010 Jul; 70(1):102-8. PubMed ID: 20642552
[TBL] [Abstract][Full Text] [Related]
16. Online reporting of adverse drug reactions: a study from a French regional pharmacovigilance center.
Abadie D; Chebane L; Bert M; Durrieu G; Montastruc JL
Therapie; 2014; 69(5):395-400. PubMed ID: 25269141
[TBL] [Abstract][Full Text] [Related]
17. Making medicines safer: analysis of patient reports to the UK's Yellow Card Scheme.
O' Donovan B; Rodgers RM; Cox AR; Krska J
Expert Opin Drug Saf; 2019 Dec; 18(12):1237-1243. PubMed ID: 31538503
[No Abstract] [Full Text] [Related]
18. Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006.
Aagaard L; Nielsen LH; Hansen EH
Drug Saf; 2009; 32(11):1067-74. PubMed ID: 19810778
[TBL] [Abstract][Full Text] [Related]
19. Spontaneous adverse drug reaction reports for neonates and infants in the UK 2001-2010: content and utility analysis.
Hawcutt DB; Russell NJ; Maqsood H; Kouranloo K; Gomberg S; Waitt C; Sharp A; Riordan A; Turner MA
Br J Clin Pharmacol; 2016 Dec; 82(6):1601-1612. PubMed ID: 27597136
[TBL] [Abstract][Full Text] [Related]
20. The importance of direct patient reporting of suspected adverse drug reactions: a patient perspective.
Anderson C; Krska J; Murphy E; Avery A;
Br J Clin Pharmacol; 2011 Nov; 72(5):806-22. PubMed ID: 21496066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
